Hematological and Immunological Markers of Response to Selective Serotonin Reup take Inhibitors in Patients with Major Depressive Disorder

الموضوعات

طب

الملخص

Major depressive disorder (MDD) is a psychiatric disorder that is characterized by long-lasting sadness, depressed mood and loss of pleasure in life activities. It is the most prevalent mental health problem in the West Bank, Palestine, affecting around 30% of Palestinians. Recent studies argue that MDD can result from disruption to particular hematologicaland immunologicalpath ways. Only 30% of patients with MDD respond to pharmacological modalities for treating MDD, the most commonly used of which are selective serotonin reuptake inhibitors (SSRIs). Unfortunately, there are no tools that can help predict in advance which MDD patient will, or will not respond to SSRIs. The aim of this study is to investigate immunological and hematological markers that have the potential to a prioripredict response to SSRI antidepressants in patients with MDD to provide the field of psychiatry with valuable tools to select the appropriate treatment for the appropriate patient.We recruited 8 medication-naïve patients with MDD from different psychiatric clinics in the West Bank, Palestine. These patients never received any form of treatment. Further, we tested 8 matched healthy control subjects. Patients with MDD were tested twice; (1) at baseline, upon diagnosis with MDD, and (2) 4-6 weeks after receiving SSRI treatment (estimated time for clinical improvement). Patients were assigned to two groups according to their response to SSRI treatment: (1) SSRI-responders and (2) SSRI-non-responders. Healthy subjects were also tested twice, 4-6 weeks apart. A peripheral blood sample was collected using an EDTA tube (10 mL) from each subject per session to investigate the levels of the following cytokines: IL-2, IL-6, IL-10, IFN-γ, MIF as well as for CRP quantification using ELISA. Further, we prepared blood films manually and examined them to obtain a differential count of the white blood cells. Our results showed that SSRI-responders and SSRI non-responders show trending differences at baseline in bothcytokine levels and cell counts. In particular, SSRI-responders show higher levels of both pro-inflammatory and anti-inflammatory cytokines. Conversely, non-responders showed relatively lower levels of pro-inflammatory and anti-inflammatory cytokines. Hematological markers differentiated patients with MDD from healthy controls with higher levels of lymphocytes and lower levels of neutrophils and eosinophils. After treatment, SSRI- ivresponders, but not non-responders, showed a relative decrease in pro-inflammatory cytokines and lymphocytes. These results could present an initial signal for potential a priori molecular markers of response to SSRI in patients with MDD. With sufficient recruitment of patients, we anticipate that statistical classification models can produce significant differences between responders and non-responders using the immunological and hematological markers under investigation in this study.

روابط وملفات

التعريف والنوع

رقم الوثيقة

08139a2f-e1f1-4782-a537-85a48bfbefef

رقم العقد

0

نوع الوسائط

Crawler

نوع المحتوى

الرسائل العلمية

صيغة المصدر

رسائل ماجيستير

نوع الملف

pdf text

أسماء الملفات

1696619_1.pdf

بيانات النشر

ترجمة العنوان

دراسة استجابة مرضى الاكتئاب السريري لمثبطات استرجاع السيروتونين الانتقائية من خلال جزيئات مناعية ودموية معينة

ألقاب المؤلفين

[{"name_ar":"حماد حرزالله","title_ar":"اشراف","title_en":"Supervision"},{"name_ar":"رحمه يوسف سعيد النتشه","title_ar":"اعداد","title_en":"Preparation"}]

اللغة

English

المصدر والدورية

اسم المصدر

Hematological and Immunological Markers of Response to Selective Serotonin Reup take Inhibitors in Patients with Major Depressive Disorder

المحتوى والصفحات

عدد الصفحات

0

إشراف وإعداد

الإشراف

حماد حرزالله

الإعداد

رحمه يوسف سعيد النتشه

الاقتباسات الببليوغرافية